figshare
Browse
iann_a_1523550_sm0933.docx (15.96 kB)

Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis

Download (15.96 kB)
journal contribution
posted on 2018-11-19, 11:06 authored by Eduard Brunet, Cristina Roig-Ramos, Emili Vela, Montserrat Clèries, Luigi Melcarne, Albert Villòria, Caridad Pontes, Xavier Calvet

Introduction: Few recent data on the epidemiology of inflammatory bowel disease (IBD) are available, especially in Southern Europe.

Aim: To evaluate the prevalence, incidence and mortality of IBD in Catalonia during the period 2011–2016.

Material and methods: Data on the prevalence, incidence and mortality of IBD were obtained from the Catalan Health Surveillance System (CHSS). Crude incidence and prevalence rates were calculated for all the Catalan population. Trends in age-sex-adjusted rates were also estimated, and logistic regression was used to calculate the adjusted mortality odds ratio (OR). Data for Crohn’s disease (CD) and ulcerative colitis (UC) were analyzed separately.

Results: The prevalence per 100,000 inhabitants in 2016 was 353.9 for UC and 191.4 for CD. The total number of IBD patients rose from 29543 in 2011 to 40614 in 2016. IBD was associated with significantly elevated adjusted mortality ratios: 1.28 (95% CI: 1.6–1.4) for UC and 1.85 (95% CI: 1.62–2.12) for CD.

Conclusions: IBD prevalence is very high and is increasing rapidly in Catalonia. Both CD and UC are associated with significantly higher mortality rates.Key message

Crohn disease and ulcerative colitis present a small but significant increase in mortality compared to non-inflammatory bowel disease.

The prevalence of inflammatory bowel disease is increasing rapidly in Catalonia.

Data on prevalence and incidence suggest that the number of patients may double in approximately 10 years.

Crohn disease and ulcerative colitis present a small but significant increase in mortality compared to non-inflammatory bowel disease.

The prevalence of inflammatory bowel disease is increasing rapidly in Catalonia.

Data on prevalence and incidence suggest that the number of patients may double in approximately 10 years.

Funding

This was partially funded by Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (SGR01500) and CIBERehd.

History